View in EDS HTML Full Text PDF Full Text

Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma.

Saved in:
Bibliographic Details
Title: Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma.
Authors: Yonemoto, Takuya1 (AUTHOR), Ogasawara, Sadahisa1 (AUTHOR) ogasawaras@chiba-u.jp, Kanogawa, Naoya1 (AUTHOR), Miwa, Chihiro1 (AUTHOR), Fujiya, Makoto1 (AUTHOR), Tsuchiya, Takahiro1 (AUTHOR), Sawada, Midori1 (AUTHOR), Akatsuka, Teppei1 (AUTHOR), Izai, Ryo1 (AUTHOR), Yumita, Sae1 (AUTHOR), Nakagawa, Miyuki2 (AUTHOR), Okubo, Tomomi3 (AUTHOR), Koroki, Keisuke1 (AUTHOR), Inoue, Masanori1 (AUTHOR), Nakamura, Masato1 (AUTHOR), Kondo, Takayuki1 (AUTHOR), Nakamoto, Shingo1 (AUTHOR), Itokawa, Norio3 (AUTHOR), Atsukawa, Masanori3 (AUTHOR), Itobayashi, Ei2 (AUTHOR)
Source: Hepatology Research. May2025, Vol. 55 Issue 5, p718-729. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:13866346
DOI:10.1111/hepr.14160